Celldex Therapeutics Inc. is initiating a pilot study testing the ability of CDX-301, a recombinant FMS-like tyrosine kinase 3 (Flt3) ligand it licensed from Amgen Inc. in March 2009, to mobilize and improve transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies.